Donald A Berry

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Bayesian clinical trials
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 447, Houston, Texas 77030 4009, USA
    Nat Rev Drug Discov 5:27-36. 2006
  2. ncbi request reprint Clinical trials: is the Bayesian approach ready for prime time? Yes!
    Donald A Berry
    Department of Biostatistics and Applied Mathematic, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 447, Houston, TX 77030 4009, USA
    Stroke 36:1621-2. 2005
  3. ncbi request reprint Bayesian predictions of final outcomes: regulatory approval of a spinal implant
    Bailey Lipscomb
    Medtronic Sofamor Danek Inc, Memphis, Tennessee, USA
    Clin Trials 2:325-33; discussion 334-9, 364-78. 2005
  4. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
  5. ncbi request reprint The difficult and ubiquitous problems of multiplicities
    Donald A Berry
    Department of Biostatistics, M D Anderson Cancer Center, Houston, TX, USA
    Pharm Stat 6:155-60. 2007
  6. ncbi request reprint Breast cancer screening: controversy of impact
    Donald A Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA Electronic address
    Breast 22:S73-6. 2013
  7. doi request reprint Multiplicities in cancer research: ubiquitous and necessary evils
    Donald Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1400 Pressler St, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA
    J Natl Cancer Inst 104:1124-32. 2012
  8. doi request reprint Adaptive clinical trials in oncology
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA
    Nat Rev Clin Oncol 9:199-207. 2012
  9. doi request reprint Bayesian approaches for comparative effectiveness research
    Donald A Berry
    Department of Biostatistics 1409, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Trials 9:37-47. 2012
  10. doi request reprint Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:638-44. 2012

Detail Information

Publications82

  1. ncbi request reprint Bayesian clinical trials
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 447, Houston, Texas 77030 4009, USA
    Nat Rev Drug Discov 5:27-36. 2006
    ..Here, I explain the rationale underlying Bayesian clinical trials, and discuss the potential of such trials to improve the effectiveness of drug development...
  2. ncbi request reprint Clinical trials: is the Bayesian approach ready for prime time? Yes!
    Donald A Berry
    Department of Biostatistics and Applied Mathematic, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 447, Houston, TX 77030 4009, USA
    Stroke 36:1621-2. 2005
  3. ncbi request reprint Bayesian predictions of final outcomes: regulatory approval of a spinal implant
    Bailey Lipscomb
    Medtronic Sofamor Danek Inc, Memphis, Tennessee, USA
    Clin Trials 2:325-33; discussion 334-9, 364-78. 2005
    ..Our study provides an example in which Bayesian predictive modeling provided earlier information than otherwise and therefore it shortened the time line of the development of a therapeutic strategy...
  4. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  5. ncbi request reprint The difficult and ubiquitous problems of multiplicities
    Donald A Berry
    Department of Biostatistics, M D Anderson Cancer Center, Houston, TX, USA
    Pharm Stat 6:155-60. 2007
    ..So we will never be able to use a software package with default settings to resolve all problems of multiplicities. Every problem has unique aspects. And all problems require understanding the substantive area of application...
  6. ncbi request reprint Breast cancer screening: controversy of impact
    Donald A Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA Electronic address
    Breast 22:S73-6. 2013
    ..I also discuss ways for communicating the associated risks to women who have to decide whether screening (and what screening strategy) is right for them...
  7. doi request reprint Multiplicities in cancer research: ubiquitous and necessary evils
    Donald Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1400 Pressler St, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA
    J Natl Cancer Inst 104:1124-32. 2012
    ..However, the lessons apply quite generally. I consider both frequentist and Bayesian statistical approaches...
  8. doi request reprint Adaptive clinical trials in oncology
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, 4 5062 Pickens Academic Tower, Houston, TX 77030 1402, USA
    Nat Rev Clin Oncol 9:199-207. 2012
    ..A wholly new paradigm for drug development exemplifying personalized medicine is evinced by an adaptive trial called I-SPY2, in which drugs from many companies are evaluated in the same trial--a phase II screening process...
  9. doi request reprint Bayesian approaches for comparative effectiveness research
    Donald A Berry
    Department of Biostatistics 1409, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Trials 9:37-47. 2012
    ..The Bayesian statistical approach is ideally suited for such investigations because it is inherently synthetic and because it is philosophically uninhibited regarding the ability to analyze all the available evidence...
  10. doi request reprint Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:638-44. 2012
    ....
  11. doi request reprint High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
    Donald A Berry
    Division of Quantitative Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3214-23. 2011
    ..Individual trials have had limited power to show overall benefit or benefits within subsets...
  12. ncbi request reprint Commentary: screening mammography: a decision analysis
    Donald Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 447, Houston, TX 77030 4009, USA
    Int J Epidemiol 33:68; discussion 69-73. 2004
  13. ncbi request reprint Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Clin Trials 2:295-300; discussion 301-4, 364-78. 2005
    ..Such modeling also enables earlier decision making. Case studies 2 and 3 deal with trials that were shorter and smaller, respectively, because of such modeling...
  14. ncbi request reprint Effect of screening and adjuvant therapy on mortality from breast cancer
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 353:1784-92. 2005
    ..We used modeling techniques to assess the relative and absolute contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer mortality in the United States from 1975 to 2000...
  15. pmc Using molecular sizes of simple sequence repeats vs. discrete binned data in assessing probability of ancestry: application to maize hybrids
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Genetics 170:365-74. 2005
    ..We demonstrate the algorithm's utility and robustness through simulations of levels of missing and misscored molecular-size data...
  16. pmc Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varieties
    Donald A Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Genetics 165:331-42. 2003
    ..We include simulations of additional levels of missing and mistyped data to show the algorithm's utility and flexibility...
  17. ncbi request reprint Commentary: the hazards of survival comparisons
    Donald Berry
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Oncologist 12:510-1. 2007
  18. doi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3224-31. 2011
    ....
  19. doi request reprint The science of doping
    Donald A Berry
    Division of Quantitative Sciences, Department of Biostatistics, MD Anderson Cancer Center, University of Texas, 1400 Pressler Street, Houston, Texas 77030 1402, USA
    Nature 454:692-3. 2008
  20. ncbi request reprint Biomarker studies and other difficult inferential problems: statistical caveats
    Donald A Berry
    The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S17-22. 2007
    ..A related concern is subset analysis. I give a statistical argument that estrogen-receptor status is predictive of the benefits of chemotherapy in node-positive breast cancer...
  21. ncbi request reprint Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Am Heart J 145:1036-45. 2003
    ..One of these studies included 2 doses of atorvastatin, and substantial additional information is available in the literature about the effect of atorvastatin on LDL-C level lowering...
  22. ncbi request reprint BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
    Donald A Berry
    Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2701-12. 2002
    ....
  23. ncbi request reprint Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality
    Donald Berry
    Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Clin Trials 6:28-41. 2009
    ..Many studies including meta-analyses have evaluated the efficacy and safety of vitamin E and have yielded varying results. Illuminating and resolving these disparities requires addressing study variability and model uncertainty...
  24. ncbi request reprint Role of detection method in predicting breast cancer survival: analysis of randomized screening trials
    Yu Shen
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1195-203. 2005
    ..We also address whether method of detection is an independent prognostic factor in breast cancer...
  25. pmc Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbreds
    Donald A Berry
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Genetics 161:813-24. 2002
    ..We present data from 54 maize hybrids and 586 maize inbreds that were profiled using 195 SSR loci including simulations of additional levels of missing and mistyped data to demonstrate the utility and flexibility of this algorithm...
  26. ncbi request reprint Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods
    Swati Biswas
    Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Genet Epidemiol 29:141-54. 2005
    ..Such an approach will be even more important as additional information about the genetics of various cancers becomes available...
  27. pmc Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience
    Wenli Dong
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 17:1096-103. 2008
    ..To assess the effect of tumor detection method (screening versus symptom-based diagnosis) in predicting breast cancer survival and investigate how biological features of breast cancer are related to the tumor detection method...
  28. ncbi request reprint A parallel phase I/II clinical trial design for combination therapies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 63:429-36. 2007
    ..The simulations show that the proposed design saves sample size, has better power, and efficiently assigns more patients to doses with higher efficacy levels...
  29. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  30. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  31. pmc Using short-term response information to facilitate adaptive randomization for survival clinical trials
    Xuelin Huang
    Department of Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, U S A
    Stat Med 28:1680-9. 2009
    ..The new design uses fewer patients, and can more effectively assign patients to the better treatment arms. We demonstrate these properties through simulation studies...
  32. ncbi request reprint The decrease in breast-cancer incidence in 2003 in the United States
    Peter M Ravdin
    Department of Biostatistics, M D Anderson Cancer Center, Houston, USA
    N Engl J Med 356:1670-4. 2007
    ..The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded...
  33. pmc High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:5700-6. 2009
    ..To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer...
  34. ncbi request reprint Seamlessly expanding a randomized phase II trial to phase III
    Lurdes Y T Inoue
    Department of Biostatistics, University of Washington, Box 357232, Seattle, Washington 98195, USA
    Biometrics 58:823-31. 2002
    ....
  35. ncbi request reprint Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials
    Scott M Berry
    aBerry Consultants, LLC, Austin, TX, USA
    Clin Trials 10:720-34. 2013
    ..Treatment effects in various subpopulations may provide some information about treatment effects in other subpopulations...
  36. doi request reprint A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug
    Scott M Berry
    Berry Consultants, College Station, TX, USA
    Clin Trials 7:121-35. 2010
    ....
  37. doi request reprint Detecting an overall survival benefit that is derived from progression-free survival
    Kristine R Broglio
    Department of Statistics, Texas A and M University, College Station, TX, USA
    J Natl Cancer Inst 101:1642-9. 2009
    ..In some disease and treatment settings, an improvement in PFS does not result in an improved OS...
  38. ncbi request reprint Adaptive trial design
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Adv Hematol Oncol 5:522-4. 2007
  39. pmc Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center
    Swati Biswas
    Department of Biostatistics, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, USA
    Clin Trials 6:205-16. 2009
    ..The Bayesian approach is being used increasingly in medical research. In particular, it has become a standard in designing clinical trials at the University of Texas M. D. Anderson Cancer Center...
  40. pmc Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
    Stephen J Schuster
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 29:2787-94. 2011
    ..To determine the clinical benefit of this vaccine, we conducted a double-blind multicenter controlled phase III trial...
  41. ncbi request reprint Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  42. pmc Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    J Clin Oncol 29:294-302. 2011
    ....
  43. ncbi request reprint Revision of the American Joint Committee on Cancer staging system for breast cancer
    S Eva Singletary
    University of Texas M D Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 20:3628-36. 2002
    ..To revise the American Joint Committee on Cancer staging system for breast carcinoma...
  44. ncbi request reprint Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030 4009, USA
    Surg Clin North Am 83:803-19. 2003
    ..By increasing the number of prognostic markers that can give independent information about patient outcome, physicians will be better able to determine optimal treatment approaches for individual patients...
  45. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  46. pmc Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Gautam Borthakur
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:73-8. 2010
    ..Complete remission was achieved in 2 of 6 minimally pre-treated patients. We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory AML...
  47. ncbi request reprint Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1337-42. 2004
    ..We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer...
  48. doi request reprint Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009
    Filip Janku
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6356-63. 2012
    ..We analyzed the outcomes of single-agent phase II clinical trials in non-small cell lung cancer (NSCLC) to determine trial parameters that predicted clinical activity...
  49. ncbi request reprint Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
    Susan O'Brien
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77230, USA
    Br J Haematol 158:581-8. 2012
    ..25% in controls. Elacytarabine has monotherapy activity in patients with advanced AML. This study provides proof-of-concept that lipid esterification of nucleoside analogues is clinically relevant...
  50. ncbi request reprint General keynote: clinical trial design
    Donald A Berry
    University of Texas M D Anderson Cancer Center, USA
    Gynecol Oncol 88:S114-6; S122-3. 2003
  51. ncbi request reprint Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1459-66. 2006
    ..The aim of the current study was to develop and validate nomograms for predicting residual tumor size and probability of a patient becoming eligible for breast conservation surgery after NACT...
  52. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  53. pmc A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD
    Swati Biswas
    Department of Biostatistics, The University of North Texas Health Sciences Center, Fort Worth, TX 76107 2699, USA
    BMC Genet 6:S138. 2005
    ..We had knowledge of the simulation models at the time we performed the analyses...
  54. ncbi request reprint Building and validating a prognostic index for biomarker studies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biomark 2:97-101. 2006
    ..The prognostic index gets its power from combining prognostic biomarkers. It can be very powerful even when there are few markers that are predictive...
  55. ncbi request reprint Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma
    Camilo Jimenez
    Department of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, Texas, USA
    J Bone Miner Res 20:1562-8. 2005
    ..However, the presence of hyperparathyroidism may modify the histologic and cytologic features of osteosarcoma...
  56. ncbi request reprint High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 20:743-50. 2002
    ..To assess survival of patients with metastatic breast cancer treated with high-dose chemotherapy (HDC) versus standard-dose chemotherapy (SDC)...
  57. pmc MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation
    Jer Yen Yang
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Unit 108, Houston, TX 77030, USA
    Mol Cell Biol 26:7269-82. 2006
    ..This novel MDM2-regulated pathway is likely to play a biologically relevant role in cancer metastasis...
  58. pmc DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
    Lanlan Shen
    Department of Leukemia and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:605-13. 2010
    ..Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS...
  59. doi request reprint From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 9:643-53. 2012
    ..We review the current status of biomarker development in lymphoma, and discuss novel biomarker-directed clinical trial designs for lymphoma...
  60. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....
  61. ncbi request reprint The Bayesian principle: can we adapt?
    Donald A Berry
    Stroke 36:1623-4. 2005
  62. ncbi request reprint The past is the future: innovative designs in acute stroke therapy trials
    Michael Krams
    Pfizer Global Research and Development, Groton, Conn, USA
    Stroke 36:1341-7. 2005
  63. ncbi request reprint Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
    Anthony J Guidi
    North Shore Medical Center, Salem, MA, USA
    J Clin Oncol 20:732-42. 2002
    ..However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied...
  64. ncbi request reprint Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model
    Scott M Berry
    Berry Consultants, 5124 Bellerive Bend, College Station, Texas 77845, USA
    Biometrics 60:418-26. 2004
    ..We give examples to illustrate our method and we describe its application to other types of problems...
  65. ncbi request reprint Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:2061-8. 2004
    ..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
  66. ncbi request reprint Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B
    Raymond B Weiss
    Walter Reed Army Medical Center, Washington, DC, USA
    J Clin Oncol 21:1825-35. 2003
    ....
  67. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  68. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  69. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  70. pmc Validity of models for predicting BRCA1 and BRCA2 mutations
    Giovanni Parmigiani
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
    Ann Intern Med 147:441-50. 2007
    ..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood...
  71. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  72. ncbi request reprint Breast cancer trends: a marriage between clinical trial evidence and epidemiology
    Donald A Berry
    J Natl Cancer Inst 99:1139-41. 2007
  73. doi request reprint Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
    Blase N Polite
    The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 26:2659-65. 2008
    ..This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials...
  74. doi request reprint Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer
    Thomas B Julian
    Allegheny Breast Care Center, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, USA
    J Clin Oncol 26:3338-45. 2008
    ..We present the results from a large, prospective evaluation of the first rapid molecular SLN test, the Breast Lymph Node (BLN) Assay...
  75. ncbi request reprint Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis
    Jean Louis Pujol
    Institut Universitaire de Recherche Clinique, Montpellier, Cedex, France
    J Thorac Oncol 2:397-401. 2007
    ....
  76. ncbi request reprint Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, Torrance, California 90509, USA
    Clin Trials 4:5-14. 2007
    ..For the frequentist, they have well-characterized type I and II error rates and in some cases lead to a reduction in the mean sample size...
  77. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  78. ncbi request reprint Limited family structure and breast cancer risk
    Edwin S Iversen
    JAMA 298:2007; author reply 2007-8. 2007
  79. pmc Characterization of BRCA1 and BRCA2 mutations in a large United States sample
    Sining Chen
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Clin Oncol 24:863-71. 2006
    ..Existing studies have focused on Ashkenazi Jews (AJ) or on families from outside the United States. In this article, we consider the US population using the largest US-based cohort to date of both AJ and non-AJ families...
  80. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  81. ncbi request reprint Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses
    Charles H Hennekens
    Mount Sinai Medical Center Miami Heart Institute, Department of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Boca Raton, FL 33432, USA
    Arch Intern Med 164:40-4. 2004
    ..Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits...
  82. ncbi request reprint Bayesian statistics
    Donald A Berry
    Med Decis Making 26:429-30. 2006